USA Financial Formulas’s Corcept Therapeutics CORT Stock Holding History

USA Financial Formulas’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-767	Closed	-$56.3K	–	269
2025 Q2	$56.3K	Buy	+767	New	+$55.6K	0.01%	201
2025 Q1	–	Sell	-1,065	Closed	-$53.7K	–	297
2024 Q4	$53.7K	Buy	+1,065	New	+$55.8K	0.01%	235
2021 Q1	–	Sell	-2,401	Closed	-$63K	–	353
2020 Q4	$63K	Buy	+2,401	New	+$50.6K	0.05%	169
2020 Q3	–	Sell	-17,606	Closed	-$296K	–	330
2020 Q2	$296K	Buy	+17,606	New	+$247K	0.22%	67
2017 Q4	–	Sell	-34,091	Closed	-$658K	–	275
2017 Q3	$658K	Buy	+34,091	New	+$508K	0.16%	119
2017 Q1	–	Sell	-38,601	Closed	-$280K	–	257
2016 Q4	$280K	Buy	+38,601	New	+$302K	0.07%	198

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

USA Financial Formulas's CORT Position: Q3 2025 in Review

USA Financial Formulas sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 767 shares — an estimated $56.3K sold.

USA Financial Formulas first reported a position in CORT in Q4 2016 and held it in 6 quarters. The position peaked at $658K in Q3 2017. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

USA Financial Formulas reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
USA Financial Formulas sold 767 Corcept Therapeutics shares in Q3 2025, an estimated $56.3K.
USA Financial Formulas first reported a position in Corcept Therapeutics in Q4 2016 and held it in 6 quarters.
USA Financial Formulas's Corcept Therapeutics position peaked at $658K in Q3 2017.
429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on USA Financial Formulas's 13F filing for Q3 2025, filed 10 Oct 2025.